Sequent Scientific Limited
₹218.50-₹6.35 (-2.8%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹8,288 Cr
- P/E
- 531.0x
- EV / EBITDA
- 633.5x
- Revenue
- ₹178 Cr
- Net margin
- 0.6%
- ROCE
- -2.4%
Price chart
Technical chartScreen technicals →+2.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -7.4%
- 3M
- -13.3%
- 6M
- +7.0%
- 1Y
- +2.4%
- 5Y
- +20.9%
52-week range
Day change -₹6.35 (-2.8%) from ₹225 to ₹219 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in VIYASH, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong short-term liquidity — current ratio of 21.11x
Concerns1
- Low return on equity of 0.1%
Rule-based from financial data. Not advice.
About the company
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services.
Read moreShow less
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.
- Sector
- Healthcare
- Shares outstanding
- 43.6 Cr shares
- ISIN
- INE807F01027
- BSE code
- 512529
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹8,288 Cr
- P/E
- 531.0x
- P/B
- 4.1x
- EV / EBITDA
- 633.5x
- EV / Sales
- 48.7x
- P/S
- 49.0x
- Earnings yield
- 0.2%
- 52-week high
- ₹294.20
- 52-week low
- ₹179.90
Profitability
- Operating margin
- -16.0%
- Net margin
- 0.6%
- EBITDA margin
- 7.7%
- ROE
- 0.1%
- ROCE
- -2.4%
- ROA
- 0.1%
- Dividend payout
- 0.0%
- Tax rate
- -358.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹178 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.3%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -5.7%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹13.0 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 550.0%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 1500.0%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -45.6%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹27.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -171.1%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹1.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.8%
Solvency and efficiency
- Current ratio
- 21.11
- Debt / Equity
- 0.04
- Debt / Assets
- 0.04
- Debt / EBITDA
- 3.62
- Financial leverage
- 1.09
- CFO / Net profit
- -27.00
- Cash / Market cap
- 6.0%
- Cash per share
- ₹11.46
- Asset turnover
- 0.14
- Fixed asset turnover
- 3.93
- Capital intensity
- 0.25
- Debtor days
- 97 days
- Inventory turnover
- 3.12
- Cash conversion cycle
- 88 days
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Sales | ₹178 Cr |
| Expenses | ₹190 Cr |
| Operating profit | -₹11 Cr |
| Other income | ₹46 Cr |
| Interest | ₹4 Cr |
| Depreciation | ₹9 Cr |
| Profit before tax | ₹22 Cr |
| Tax and other | ₹6 Cr |
| Net profit | ₹16 Cr |
Revenue and net profit
Revenue grew 5.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹265 Cr | ₹32 Cr |
| FY2022 | ₹220 Cr | ₹15 Cr |
| FY2023 | ₹223 Cr | -₹6 Cr |
| FY2024 | ₹169 Cr | ₹1 Cr |
| FY2025 | ₹178 Cr | ₹16 Cr |
Cash flows
FY2025: -₹1.00 Cr from operations, -₹1.00 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹2 Cr | ₹19 Cr |
| FY2022 | ₹9 Cr | ₹5 Cr |
| FY2023 | ₹38 Cr | -₹13 Cr |
| FY2024 | -₹27 Cr | -₹22 Cr |
| FY2025 | -₹1 Cr | -₹1 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹178 Cr+5.3%1Y
- Net profit
- ₹16 Cr+1,500.0%1Y
- Cash from operations
- -₹1 Cr
- Free cash flow
- -₹1 Cr
- Revenue CAGR, 5Y
- -5.7%
- EBITDA CAGR, 5Y
- -18.9%
- Net profit CAGR, 5Y
- -45.6%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹178 Cr | -₹11 Cr | — | ₹16 Cr | -₹1 Cr | -₹1 Cr | 1.4% | +5.3% | +1500.0% |
Monthly returns
Month-by-month returns of VIYASH across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,222 Cr |
| Equity capital | ₹50 Cr |
| Reserves | ₹1,093 Cr |
| Borrowings | ₹46 Cr |
| Other liabilities | ₹34 Cr |
| Assets | ₹1,222 Cr |
| Fixed assets | ₹46 Cr |
| Capital work in progress | ₹7 Cr |
| Investments | ₹647 Cr |
| Other assets | ₹522 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
VIYASH trades at 531.0x earnings against a peer median of 52.6x (a 910% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Sequent Scientific LimitedVIYASHthis companyP/E ↑ premium | ₹8,288 Cr | 531.0x | 4.1x | 0.1% | 633.5x |
| Sanofi India LtdSANOFI | ₹9,387 Cr | 25.4x | 12.0x | — | — |
| Jeena Sikho Lifecare LimitedJSLL | ₹8,968 Cr | 58.2x | 25.2x | 35.9% | 90.3x |
| PROCTER & GAMBLE HEALTH LIMITEDPGHL | ₹8,946 Cr | 29.2x | 14.4x | — | — |
| Jupiter Life Line Hospitals LimitedJLHL | ₹8,877 Cr | 46.3x | 5.9x | 12.2% | 34.5x |
| Corona Remedies LimitedCORONA | ₹8,749 Cr | 55.1x | — | 18.8% | 55.0x |
| Blue Jet Healthcare LimitedBLUEJET | ₹8,659 Cr | 24.6x | 6.9x | 19.4% | 34.4x |
| STRIDES PHARMA SCIENCE LIMITEDSTAR | ₹8,552 Cr | 112.0x | 2.7x | 1.3% | 35.5x |
| Marksans Pharma Ltd.MARKSANS | ₹7,873 Cr | 32.7x | 5.3x | 11.0% | 38.1x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
VIYASH since 1 January, against earlier years.
Historical volatility
VIYASH's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 13.0% |
| FY2022 | 0.0% |
| FY2023 | -12.0% |
| FY2024 | -16.0% |
| FY2025 | -6.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹178 Cr |
| Costs | |
| Interest | ₹4 Cr |
| Expenses | ₹190 Cr |
| Operating profitOperating Profit | -₹11 Cr |
| Other income and charges | |
| Profit before tax | ₹22 Cr |
| Tax | |
| Net profitNet Profit | ₹16 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,222 Cr |
| Equity capitalEquity Capital | ₹50 Cr |
| Reserves | ₹1,093 Cr |
| Borrowings | ₹46 Cr |
| Other liabilitiesOther Liabilities | ₹34 Cr |
| AssetsTotal Assets | ₹1,222 Cr |
| Fixed assetsFixed Assets | ₹46 Cr |
| Capital work in progressCWIP | ₹7 Cr |
| Investments | ₹647 Cr |
| Other assetsOther Assets | ₹522 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | -₹1 Cr |
| Investing cash flowCash from Investing Activity | ₹0 Cr |
| Financing cash flowCash from Financing Activity | ₹1 Cr |
| Change in cashNet Cash Flow | -₹1 Cr |
Learn while you research
Academy chapters picked for Sequent Scientific Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 531.0, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read